Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 2,124 matching trials from the live ClinicalTrials.gov search.
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
sirolimus, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
Interventions
LY2584702, Erlotinib, Everolimus
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Cancer
Interventions
EPC2407 (crinobulin)
Drug
Lead sponsor
EpiCept Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Beverly Hills, California • San Diego, California
Completed Phase 1Phase 2 Interventional Results available

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

NCT02264613
Conditions
Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
Interventions
ALRN-6924
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Denver, Colorado + 9 more
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Conditions
Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, Malignancy
Interventions
CVX-045
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Santa Monica, California • Philadelphia, Pennsylvania
Conditions
Solid Tumors
Interventions
Atezolizumab, RO6958688
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Santa Monica, California • Stanford, California • Aurora, Colorado + 7 more
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Interventions
JAB-3312
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas + 1 more
Conditions
Cancer,, Solid Tumors, Advanced Solid Malignancies
Interventions
AZD6918, gemcitabine, pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Conditions
Solid Tumors, Advanced Solid Tumor
Interventions
BG-C0902
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant human endostatin
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Advanced/Metastatic Malignant Solid Tumors
Interventions
HLX43, HLX10
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Conditions
Adult Solid Neoplasm, Toxicity, Lymphoma
Interventions
Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Survey Administration
Other
Lead sponsor
Supriya Mohile
Other
Eligibility
70 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
23
States / cities
Duarte, California • Newark, Delaware • Honolulu, Hawaii + 20 more
Conditions
Neoplastic Disease
Interventions
ABI-011
Drug
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Conditions
Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal
Interventions
CBP-1019
Drug
Lead sponsor
Coherent Biopharma (Hefei) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Cerritos, California • Orlando, Florida • Manhasset, New York + 1 more
Conditions
Solid Tumors, Lymphomas
Interventions
FF-10502-01
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Conditions
Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST, Ovarian Cancer
Interventions
HER-2 vaccine, Extension HER-2 vaccine trial at OBD
Biological
Lead sponsor
Robert Wesolowski
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Cancer, Metastatic Cancer, Germ Cell Tumor
Interventions
DS-9606a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Fort Myers, Florida • Detroit, Michigan + 2 more
Conditions
Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions
Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
14
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 10 more
Conditions
Metastatic Solid Tumors
Interventions
ERAS-4001, ERAS-4001 in combination
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Nashville, Tennessee • Houston, Texas • Irving, Texas + 2 more
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
REGN6569, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
retifanlimab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • New Brunswick, New Jersey + 4 more
Conditions
Cancer
Interventions
CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab, CGC-11047 and erlotinib, CGC-11047 and cisplatin, CGC-11047 and 5-flurouracil / leucovorin, CGC-11047 and sunitinib
Drug
Lead sponsor
Progen Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more